

Zaina Al Kanaani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8281026/publications.pdf>

Version: 2024-02-01

27
papers

3,107
citations

394421

19
h-index

526287

27
g-index

51
all docs

51
docs citations

51
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	5.8	38
2	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	2.5	1
3	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	2.7	7
4	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	5.8	154
5	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	2.7	71
6	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	2.3	22
7	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	3.3	117
8	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.7	27
9	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.9	58
10	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	4.3	74
11	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	69
12	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	7.1	153
13	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>IScience</i> , 2021, 24, 102646.	4.1	79
14	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	3.3	14
15	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	30.7	337
16	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	3.3	49
17	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	27.0	675
18	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	7.4	140

#	ARTICLE	IF	CITATIONS
19	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	30.7	346
20	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	8.4	54
21	Key associations for hepatitis C virus genotypes in the Middle East and North Africa. <i>Journal of Medical Virology</i> , 2020, 92, 386-393.	5.0	10
22	Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 Februaryâ€“18 April 2020. <i>BMJ Open</i> , 2020, 10, e040428.	1.9	82
23	The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. <i>Addiction</i> , 2020, 115, 1244-1262.	3.3	23
24	Hepatitis C Virus Infection in Populations With Liverâ€“Related Diseases in the Middle East and North Africa. <i>Hepatology Communications</i> , 2020, 4, 577-587.	4.3	5
25	Characterization of the hepatitis C virus epidemic in Pakistan. <i>BMC Infectious Diseases</i> , 2019, 19, 809.	2.9	24
26	Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. <i>Annals of Epidemiology</i> , 2018, 28, 452-461.	1.9	20
27	The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. <i>Royal Society Open Science</i> , 2018, 5, 180257.	2.4	83